CASI Pharmaceuticals (CASI) Earns Coverage Optimism Score of 0.14

Media headlines about CASI Pharmaceuticals (NASDAQ:CASI) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.2186993669334 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

CASI Pharmaceuticals (CASI) traded down $0.03 on Monday, hitting $3.75. The stock had a trading volume of 256,600 shares, compared to its average volume of 492,074. The stock has a market cap of $244.00, a PE ratio of -31.25 and a beta of 1.08. CASI Pharmaceuticals has a 52 week low of $0.91 and a 52 week high of $4.84.

CASI Pharmaceuticals (NASDAQ:CASI) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. equities analysts expect that CASI Pharmaceuticals will post -0.13 EPS for the current fiscal year.

Separately, Maxim Group set a $4.00 price objective on CASI Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 14th.

COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Insider Buying and Selling by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply